AFP and hepatocellular carcinoma: In general, our study showed that camrelizumab plus lenvatinib and camrelizumab plus apatinib appeared to be more effective than camrelizumab plus sorafenib in the adjuvant therapy of HCC patients with the camrelizumab combined with different anti-angiogenic targeted drugs, which was also confirmed by postoperative AFP, ALT, and AST level analysis.